{
  "id": 7225051,
  "title": "Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer",
  "url": "https://urgent.news/2026/09/14/zipalertinib-plus-chemotherapy-significantly-extends-progression-free",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T01:50:10.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-zipalertinib-chemotherapy-significantly-free-survival.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Zipalertinib plus chemo shows survival benefit in lung cancer trial",
        "url": "https://urgent.news/2026/09/13/zipalertinib-plus-chemo-shows-survival-benefit-in-lung-cancer-trial",
        "published": "2026-09-13T23:20:40.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}